Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: Findings from four Phase 3 trials

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages 396-402

  Eriksson, Bengt I ^a   Smith, John J ^b   Caprini, Joseph ^c   Hantel, Stefan ^d   Clemens, Andreas ^d   Feuring, Martin ^d   Schnee, Janet ^b   Barsness, Gregory W ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e MAYO CLINIC   (United States)

Author keywords

Acute coronary syndrome; Dabigatran etexilate; Myocardial infarction; Orthopedic surgery; Venous thromboembolism

Indexed keywords

DABIGATRAN ETEXILATE; ENOXAPARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG SAFETY; HUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANTS; BENZIMIDAZOLES; DRUG TOXICITY; HUMANS; INCIDENCE; INTERNATIONALITY; MALE; MIDDLE AGED; ORTHOPEDICS; POSTOPERATIVE COMPLICATIONS; PYRIDINES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84865252122     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.05.014     Document Type: Article

References (23)

1. A.J. Busti, and H.I. Bussey The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism Pharmacotherapy 24 2004 184S 189S
2. A. Ascani, A. Iorio, and G. Agnelli Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation Blood Coagul Fibrinolysis 10 1999 291 295
3. N.R. Bijsterveld, A.H. Moons, J.C. Meijers, J.G. Tijssen, H.R. Buller, and M. Levi Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin J Am Coll Cardiol 39 2002 811 817
4. U. Genewein, A. Haeberli, P.W. Straub, and J.H. Beer Rebound after cessation of oral anticoagulant therapy: the biochemical evidence Br J Haematol 92 1996 479 485
5. C.B. Granger, J.M. Miller, E.G. Bovill, A. Gruber, R.P. Tracy, and M.W. Krucoff Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes Circulation 91 1995 1929 1935
6. C. Hermans, and D. Claeys Review of the rebound phenomenon in new anticoagulant treatments Curr Med Res Opin 22 2006 471 481
7. G. Palareti, C. Legnani, G. Guazzaloca, M. Frascaro, F. Grauso, and F. De Rosa Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants-a prospective study Thromb Haemost 72 1994 222 226
8. P. Theroux, D. Waters, J. Lam, M. Juneau, and J. McCans Reactivation of unstable angina after the discontinuation of heparin N Engl J Med 327 1992 141 145
9. N.R. Bijsterveld, R.J. Peters, S.A. Murphy, P.J. Bernink, J.G. Tijssen, and M. Cohen Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies J Am Coll Cardiol 42 2003 2083 2089
10. S.G. Goodman, A. Barr, A. Sobtchouk, M. Cohen, G.J. Fromell, and L. Laperriere Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy J Am Coll Cardiol 36 2000 1507 1513
11. L.A. Linkins, and J.I. Weitz Pharmacology and clinical potential of direct thrombin inhibitors Curr Pharm Des 11 2005 3877 3884
12. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
13. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
14. B.I. Eriksson, O.E. Dahl, M.H. Huo, A.A. Kurth, S. Hantel, and K. Hermansson Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
15. J.S. Ginsberg, B.L. Davidson, P.C. Comp, C.W. Francis, R.J. Friedman, and M.H. Huo Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
16. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 381S 453S
17. C. Clopper, and S. Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 1934 404 413
18. M.C. Bahit, E.J. Topol, R.M. Califf, P.W. Armstrong, D.A. Criger, and V. Hasselblad Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes J Am Coll Cardiol 37 2001 1001 1007
19. K.W. Mahaffey, R.A. Harrington, M. Akkerhuis, N.S. Kleiman, L.G. Berdan, and B.S. Crenshaw Systematic adjudication of myocardial infarction end-points in an international clinical trial Curr Control Trials Cardiovasc Med 2 2001 180 186
20. K.W. Mahaffey, M.T. Roe, C.K. Dyke, L.K. Newby, N.S. Kleiman, and P. Connolly Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial Am Heart J 143 2002 242 248
21. B.I. Eriksson, J.J. Smith, J.A. Caprini, S. Hantel, A. Clemens, and M. Feuring Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopaedic surgery: findings from four phase III trials Presented at: American Society of Hematology; San Diego, CA December 8-11, 2011 Abstract 2309
22. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
23. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876